Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Elaprase Prior Auth Policy | OpenPayer
    Ask Trek AI about this page
    CurrentCareSourcePolicy N/A

    Elaprase (idursulfase) for MPS II

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical prior authorization coverage for Elaprase (idursulfase), an enzyme replacement therapy for mucopolysaccharidosis type II (Hunter syndrome), for CareSource Arkansas PASSE members. It establishes diagnostic, prescriber, documentation, neurologic-status, dosing, and continuation requirements.

    Policy Summary
    PayerCareSource
    PolicyElaprase (idursulfase) for MPS II
    Policy CodePolicy N/A
    Change TypeEligibility expanded
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain medical prior authorization and submit diagnostic, baseline urinary GAG, neurologic-status, and dosing documentation for initial therapy.
    SourceLink
    POLICY UPDATE CHANGES

    The policy history states that the age limit for Elaprase coverage was removed on December 29, 2023.

    References were updated on May 5, 2026.

    0.5 mg/kg weeklyAllowed dosage and quantity limit
    6 monthsInitial authorization period
    12 monthsReauthorization period
    2Diagnostic pathways

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Severe neurologic impairment
    Coverage exclusion

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following initial authorization criteria are met:

    ALL of the following

    • Medication is prescribed by or in consultation with a geneticist, metabolic specialist, or pediatrician experienced with managing mucopolysaccharidoses.
    • Member has a diagnosis of MPS II confirmed by at least one of the following: low iduronate 2-sulfatase enzyme activity and normal activity of a second sulfatase to exclude Multiple Sulfatase Deficiency; and/or molecular genetic testing identifying a pathogenic IDS gene mutation.
    • Documentation of baseline urinary GAG (uGAG) level.
    • Member does not have severe neurologic impairment.
    • Dosage is 0.5 mg/kg by IV infusion once weekly.

      Quantity limit applies.

    Continuation Therapy

    Covered for reauthorization when the following criterion is met:

    ALL of the following

    • Chart notes show improvement or stabilization of signs and symptoms of disease compared with baseline, such as improved functional capacity (e.g., 6-minute walk test or forced vital capacity [FVC]), reduced liver and spleen volumes, and/or reduced urinary GAG (uGAG) levels.

      If this requirement is met, the medication will be approved for an additional 12 months.

    Coverage requires that the member does not have severe neurologic impairment. Examples include being in a vegetative state or being fed by gastrostomy due to inability to swallow.

    CareSource considers Elaprase (idursulfase) not medically necessary for the treatment of conditions or indications not listed in this policy. For any other indication, refer to the Off-Label policy.

    Initial Elaprase Authorization

    Initial Elaprase Authorization

    Initial Elaprase authorization requires all of the following:

    Initial Elaprase authorization

    • Qualified prescriber or consultation: Elaprase is prescribed by or in consultation with a geneticist, metabolic specialist, or pediatrician experienced with managing mucopolysaccharidoses.
    • At least 1 diagnostic pathway

      • Enzyme testing pathway: Low iduronate 2-sulfatase enzyme activity and normal activity of a second sulfatase to exclude Multiple Sulfatase Deficiency are documented.
      • Molecular testing pathway: Molecular genetic testing identifies a pathogenic IDS gene mutation.

    Elaprase Reauthorization

    Elaprase Reauthorization

    Reauthorization requires chart documentation of improvement or stabilization compared with baseline:

    Documented continuation response

    • Functional capacity is improved or stabilized compared with baseline, such as on the 6-minute walk test or forced vital capacity (FVC).Improved or stabilized compared with baseline
    • Organ volumes: Liver and spleen volumes are reduced compared with baseline.Reduced compared with baseline
    • Urinary GAG: uGAG levels are reduced compared with baseline.Reduced compared with baseline

    Dosing and Quantity Limits

    Elaprase (idursulfase)
    Dose0.5 mg/kg
    RouteIntravenous (IV) infusion
    FrequencyOnce weekly

    Clinical Documentation Measures

    Functional capacity
    Required findingImprovement or stabilization compared with baseline
    6-minute walk testImproved functional capacity compared with baseline
    Forced vital capacity (FVC)Improved functional capacity compared with baseline
    Urinary GAG
    Required findingReduced urinary GAG levels compared with baseline
    MeasureUrinary glycosaminoglycan (uGAG) level
    Use in reauthorizationDocuments an objective disease response compared with baseline

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain medical prior authorization

    Medical prior authorization is required for Elaprase. For initial authorization, the medication must be prescribed by or used in consultation with a geneticist, metabolic specialist, or pediatrician experienced with managing mucopolysaccharidoses.

    Documentation Required

    Submit initial and reauthorization documentation

    Submit documentation identifying the prescribing provider or specialist consultant and confirming MPS II through accepted enzyme activity and/or molecular genetic testing. Include a baseline urinary GAG level for initial authorization and chart notes documenting improvement or stabilization of disease signs and symptoms compared with baseline for reauthorization.

    • Confirm MPS II through low iduronate 2-sulfatase enzyme activity with normal activity of a second sulfatase, and/or molecular genetic testing identifying a pathogenic IDS gene mutation.
    • Document baseline urinary GAG (uGAG) level.

    Disease Background

    Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a rare X-linked lysosomal storage disease caused by pathogenic mutations in the IDS gene. These mutations result in deficient or absent iduronate 2-sulfatase activity, allowing glycosaminoglycans—particularly heparan sulfate and dermatan sulfate—to accumulate throughout the body and cause chronic, progressive somatic disease. Elaprase is an enzyme replacement therapy that may improve somatic manifestations but does not address neurologic symptoms because it does not cross the blood-brain barrier.

    Key Terms

    MPS II (Hunter syndrome)
    Full nameMucopolysaccharidosis type II
    Alternate nameHunter syndrome
    Disease relationshipAn X-linked lysosomal storage disease associated with deficient iduronate 2-sulfatase activity
    Iduronate 2-sulfatase
    DefinitionA lysosomal enzyme
    Alternate namesIDS or I2S
    Role in MPS IIThe enzyme is deficient or absent in MPS II
    Policy Summary
    PayerCareSource
    PolicyElaprase (idursulfase) for MPS II
    Policy CodePolicy N/A
    Change TypeEligibility expanded
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionObtain medical prior authorization and submit diagnostic, baseline urinary GAG, neurologic-status, and dosing documentation for initial therapy.
    SourceLink
    On This Page
    Coverage CriteriaInitial Elaprase AuthorizationElaprase ReauthorizationDosing and Quantity LimitsClinical Documentation MeasuresAuthorization and Documentation RequirementsDisease BackgroundKey Terms
  1. Baseline urinary GAG: A baseline urinary GAG (uGAG) level is documented.Baseline uGAG documented
  2. Neurologic status: The member does not have severe neurologic impairment, such as being in a vegetative state or being fed by gastrostomy because of inability to swallow.No severe neurologic impairment
  3. Dose and quantity: Elaprase is administered at 0.5 mg/kg by intravenous infusion once weekly.0.5 mg/kg IV once weekly
  4. Organ volumes
    Liver volumeReduced compared with baseline
    Spleen volumeReduced compared with baseline
    Use in reauthorizationDocuments an objective disease response
  5. For reauthorization, document improvement or stabilization compared with baseline, such as improved functional capacity, reduced liver and spleen volumes, or reduced uGAG levels.
  6. Denial Risk

    Verify neurologic status before requesting coverage

    Coverage may be denied when the member has severe neurologic impairment, including being in a vegetative state or requiring gastrostomy feeding because of inability to swallow.

    Denial Risk

    Do not use for unlisted indications

    Elaprase is not medically necessary for conditions or indications not listed in this policy. Refer other indications to the Off-Label policy.

    Glycosaminoglycans (GAGs)
    DefinitionGlycosaminoglycans, previously known as mucopolysaccharides
    Heparan sulfateAccumulates throughout the body when iduronate 2-sulfatase activity is reduced in MPS II
    Dermatan sulfateAccumulates throughout the body when iduronate 2-sulfatase activity is reduced in MPS II